Amgen expected to price four-part offering of senior notes

By Aleesia Forni

Virginia Beach, April 28 – Amgen Inc. plans to sell an offering of senior notes (//BBB) in four tranches, according to a 424B3 filed with the Securities and Exchange Commission.

The offering will include tranches of notes due 2020, 2022, 2025 and 2045.

Morgan Stanley & Co. LLC, BofA Merrill Lynch, Credit Suisse Securities (USA) LLC and Goldman Sachs & Co. are the bookrunners.

The company intends to use the net proceeds from this offering to repurchase additional shares of common stock under its stock repurchase program, to repay outstanding debt, including borrowings under a term loan credit agreement, and for general corporate purposes.

The manufacturer and marketer of human therapeutics based upon advances in cellular and molecular biology is based in Thousand Oaks, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.